Latest / Stock Movers / Estee Lauder Gains, Imax Jumps, Denali Therapeutics Slides After Parkinson’s Drug Trial Failure
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg data.
- 0:16Speaker 1: Let's check in with Avlon Parnell, who has our stocks
- 0:19Speaker 1: to watch up and they're on the move this morning. Avlon,
- 0:22Speaker 1: get us start it.
- 0:23Speaker 3: Yeah, we have to talk about Esday Lauder. That's ticker
- 0:25Speaker 3: el currently jumping about ten percent to its highest interday
- 0:29Speaker 3: level since March, which, if you remember, is actually when
- 0:31Speaker 3: the merger talks were confirmed. A's after Essay Lauder and
- 0:34Speaker 3: the Spanish brand Pooge agreed to end merger talks for
- 0:37Speaker 3: those unaware Essay latterers behind brands like mac Clinique and
- 0:41Speaker 3: The Ordinary, and the move was broadly seen as a
- 0:44Speaker 3: major positive for investors who believe that the merger could
- 0:46Speaker 3: potentially hinder Essay Latter's ability to turn around, and JPMorgan
- 0:51Speaker 3: also writing that they view it as a positive because
- 0:53Speaker 3: it shows that Essay Latter's management has a discipline to
- 0:56Speaker 3: walk away from potential distractions. So that's how you pronounce it, Pooge,
- 0:59Speaker 3: I was where we to pronouncing it?
- 1:01Speaker 2: What about Imax?
- 1:02Speaker 3: What's going on with the theater. Yes, that is ticker IMAX,
- 1:06Speaker 3: currently climbing sixteen percent for most inter day since February.
- 1:10Speaker 3: That's after a Wall Street Journal reports that the large
- 1:12Speaker 3: screen theater company is exploring a sale and has approached
- 1:16Speaker 3: entertainment companies as potential buyers. Worth noting obviously the sale
- 1:20Speaker 3: processants in early stages, it may not actually result in
- 1:23Speaker 3: a deal. However, Benchmark is writing that the report strongly
- 1:27Speaker 3: validates her thesis that IMAX's strategic value exceeds their current
- 1:31Speaker 3: public valuation.
- 1:32Speaker 1: Just for the record, IMAX considers itself a tech company,
- 1:35Speaker 1: a large screen and theater platform and tech platform company.
- 1:39Speaker 1: So okay. Last one for us avalon.
- 1:41Speaker 3: Yes, we have Denulli Therapeutics. That's ticker DNLI, currently sliding
- 1:46Speaker 3: about four point two percent. It was kind of hard
- 1:48Speaker 3: to find a company in the rend today, but this
- 1:51Speaker 3: biotech report that it's experimental therapy to treat Parkins's disease
- 1:54Speaker 3: failed to reach those key goals. The drug did not
- 1:57Speaker 3: slow the progression of the disease versus the placebo and
- 2:00Speaker 3: Tdcowen writing that while the outcome is a disappointment, they
- 2:03Speaker 3: do believe that the expectations were already quite low going
- 2:06Speaker 3: into the program.
- 2:08Speaker 2: The Stockmover's Report from Bloomberg Radio. Check back with us
- 2:12Speaker 2: throughout the day for the latest roundup of companies making
- 2:15Speaker 2: news on Wall Street and for the latest market moving headlines.
- 2:19Speaker 2: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
- 2:23Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 2:26Speaker 2: Bloomberg Business app.